Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions
Efficacy of Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions
This study aimed to evaluate the efficacy and safety of combining Bronchial artery embolization with bronchoscopy in the management of hemoptysis in patients with cavitary pulmonary tuberculosis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The lungs have a dual arterial supply composed of the pulmonary and bronchial arterial systems. The pulmonary arteries account for 99% of the arterial supply and are responsible for gaseous exchange.
Combining bronchoscopy with Bronchial artery embolization may improve treatment outcomes and reduce recurrence rates. Despite the increasing use of Bronchial artery embolization, limited studies have evaluated the combined role of bronchoscopy and Bronchial artery embolization specifically in patients with cavitary pulmonary tuberculosis.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mohamad B Abd-Elhafiz, MBBCH
- Phone Number: 00201140466319
- Email: mohamedbahget1990@gmail.com
Study Locations
-
-
-
Asyut, Egypt, 71511
- Recruiting
- Al-Azhar University (Assiut)
-
Contact:
- Mohamad B Abd-Elhafiz, MBBCH
- Phone Number: 00201140466319
- Email: mohamedbahget1990@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years.
- Confirmed pulmonary tuberculosis.
- Presence of cavitary lung lesions on computed tomography (CT) chest.
- Moderate or massive hemoptysis requiring intervention.
- Written informed consent.
Exclusion Criteria:
- Coagulopathy not corrected before intervention .
- Severe cardiac instability.
- Pregnancy.
- Pulmonary malignancy.
- Refusal to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group A
Patients will undergo bronchial artery embolization alone. |
Patients will undergo bronchial artery embolization alone. |
|
Experimental: Group B
Patients will undergo bronchial artery embolization combined with bronchoscopy. |
Patients will undergo bronchial artery embolization combined with bronchoscopy. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants Achieving Successful Control of Hemoptysis
Time Frame: 24 hours after completion of the assigned intervention
|
Percentage of participants achieving complete cessation of hemoptysis without requiring an additional intervention to control bleeding will be recorded. |
24 hours after completion of the assigned intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants With Recurrent Hemoptysis
Time Frame: 24 hours after completion of the assigned intervention
|
Percentage of participants experiencing a new episode of hemoptysis after initial successful bleeding control will be recorded. |
24 hours after completion of the assigned intervention
|
|
All-Cause Mortality
Time Frame: 24 hours after completion of the assigned intervention
|
Percentage of participants who die from any cause during the specified follow-up period will be recorded. |
24 hours after completion of the assigned intervention
|
|
Need for repeat embolization
Time Frame: 24 hours after completion of the assigned intervention
|
Percentage of participants requiring an additional bronchial artery embolization procedure because of persistent or recurrent hemoptysis will be recorded. |
24 hours after completion of the assigned intervention
|
|
Incidence of procedure-related complications
Time Frame: 24 hours after completion of the assigned intervention
|
Incidence of procedure-related complications will be recorded. |
24 hours after completion of the assigned intervention
|
|
Length of hospital stay
Time Frame: Till discharge from the hospital (Up to two weeks)
|
Length of hospital stay will be recorded from the admission till discharge from the hospital |
Till discharge from the hospital (Up to two weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Hemorrhage
- Lung Diseases
- Signs and Symptoms, Respiratory
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Hemoptysis
- Diagnostic Techniques and Procedures
- Diagnosis
- Surgical Procedures, Operative
- Minimally Invasive Surgical Procedures
- Diagnostic Techniques, Surgical
- Endoscopy
- Diagnostic Techniques, Respiratory System
- Thoracic Surgical Procedures
- Pulmonary Surgical Procedures
- Bronchoscopy
Other Study ID Numbers
Other Study ID Numbers
- AZFM-IRB/M-1000/2026/09/012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
IPD Sharing Time Frame
After the end of study for one year.
IPD Sharing Access Criteria
The data will be available upon a reasonable request from the corresponding author.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.